An armed HSV oncolytic viruses known as OncovexGALV/CD that combines the expression of the prodrug activating gene [yeast cytosine deaminase/uracil phospho-ribosyltransferase fusion (Fcy∷Fur)] and the fusogenic glycoprotein from gibbon ape leukemia virus (GALV), which aids the spread of the activated prodrug through the tumor, increased tumor shrinkage by five- to 10-fold in vivo compared to the non-armed virus [94]. This evidence concerns the gene ART4 and neoplasm.